GlassScriptPhysician profile
Darryl A Green
NPI 1487655619
$4,331.56
in general payments reported to CMS, 2019-2025
26 companies · $19.41 in 2025
The $19.41 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $311 · 2021: $930 · 2022: $1,319 · 2023: $772 · 2024: $769 · 2025: $19.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,560.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,408.00 | 2021-2024 | |
| Amgen INC. | $234.43 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $217.03 | 2019-2024 | Mounjaro, Trulicity |
| Allergan, INC. | $206.05 | 2020 | |
| Novartis Pharmaceuticals Corporation | $196.77 | 2021-2024 | |
| Novo Nordisk INC | $164.19 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $142.57 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.18 | 2019-2023 | Tradjenta, Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $100.56 | 2019-2024 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $75.18 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $59.94 | 2021-2023 | Belsomra |
| Astrazeneca Pharmaceuticals LP | $56.59 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.18 | 2022 | |
| Astellas Pharma US INC | $45.77 | 2021-2024 | Veozah |
| Pfizer INC. | $38.75 | 2020-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $32.72 | 2021 | |
| Mylan Specialty L.P. | $28.62 | 2019 | |
| Supernus Pharmaceuticals, INC. | $26.13 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $22.38 | 2023 | Gemtesa |
| Abbott Laboratories | $20.55 | 2023 | Freestyle Libre 2 |
| Eisai INC. | $19.96 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.40 | 2023 | Rexulti |
| Amarin Pharma, INC. | $14.44 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.26 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $14.16 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryl Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.